DAPK2 and non-small cell lung carcinoma: Decreased DAPK2 resulted in downstream activation of oncogenic nuclear factor‐κB (NF‐κB) signaling, establishing a role for the METTL3‐DAPK2‐NF‐κB axis in promoting CSC‐induced NSCLC malignancy.93